Pharvaris N.V. (PHVS): Price and Financial Metrics


Pharvaris N.V. (PHVS): $17.49

-0.51 (-2.83%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PHVS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PHVS Stock Price Chart Interactive Chart >

Price chart for PHVS

PHVS Price/Volume Stats

Current price $17.49 52-week high $22.00
Prev. close $18.00 52-week low $13.14
Day low $17.36 Volume 900
Day high $17.49 Avg. volume 12,548
50-day MA $17.47 Dividend yield N/A
200-day MA $17.05 Market Cap 556.88M

Pharvaris N.V. (PHVS) Company Bio


Pharvaris B.V. operates as a clinical-stage company. The Company focuses on the discovery and development of novel oral B2-receptor antagonists for the treatment of patients. Pharvaris serves customers in the Netherlands and Switzerland.


PHVS Latest News Stream


Event/Time News Detail
Loading, please wait...

PHVS Latest Social Stream


Loading social stream, please wait...

View Full PHVS Social Stream

Latest PHVS News From Around the Web

Below are the latest news stories about Pharvaris NV that investors may wish to consider to help them evaluate PHVS as an investment opportunity.

Pharvaris to Participate in 11th Annual SVB Leerink Global Healthcare Conference

ZUG, Switzerland, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference taking place virtually from February 14–18, 2022. The fireside chat

Yahoo | February 9, 2022

Is AllScripts Healthcare (MDRX) Outperforming Other Medical Stocks This Year?

Here is how AllScripts Healthcare (MDRX) and Pharvaris N.V. (PHVS) have performed compared to their sector so far this year.

Yahoo | January 26, 2022

Pharvaris Announces Changes to its Board of Directors

ZUG, Switzerland, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the appointment of Anne Marie de Jonge Schuermans, Ph.D., to the board of directors with expected confirmation at the company’s 2022 annual general meeting of shareholders. Dr. de

Yahoo | December 22, 2021

Pharvaris Reports Third Quarter 2021 Financial Results and Provides Business Highlights

RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks, proceeding; topline data reaffirmed for 2022CHAPTER-1, Phase 2 prophylactic study of PHVS416 for the prevention of HAE attacks, recruiting; topline data expected in 2022PHVS719 Phase 1 pharmacokinetics study initiating this monthExecuting from a strong financial position with cash and cash equivalents of €218.6 million as of September 30, 2021 ZUG, Switzerland, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS

Yahoo | November 10, 2021

7 Best Stocks Under $20 According to Billionaire Andreas Halvorsen’s Viking Global

In this article, we take a look at the 7 best stocks under $20 according to billionaire Andreas Halvorsen’s Viking Global. If you want to skip our detailed analysis of Andreas Halvorsen’s hedge fund performance, early life, and biography, skip ahead to the 3 Best Stocks Under $20 According to Billionaire Andreas Halvorsen’s Viking Global. […]

Yahoo | November 8, 2021

Read More 'PHVS' Stories Here

PHVS Price Returns

1-mo 2.34%
3-mo 2.28%
6-mo 18.90%
1-year -14.68%
3-year N/A
5-year N/A
YTD 21.54%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6502 seconds.